Long-term azithromycin therapy to reduce acute exacerbations in patients with severe chronic obstructive pulmonary disease

Respiratory Medicine

Volumn 138, Issue , 2018, Pages 129-136

  Naderi, Nafiseh ^a,b,c   Assayag, Deborah ^c   Mostafavi Pour Manshadi, Seyed Mohammad Yousof ^a,b,c   Kaddaha, Zeina ^d   Joubert, Alexandre ^a   Ouellet, Isabelle ^a   Drouin, Isabelle ^a   Li, Pei Zhi ^b   Bourbeau, Jean ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d HÔPITAL CHARLES LEMOYNE   (Canada)

Author keywords

Chronic obstructive pulmonary disease; COPD; Exacerbations; Long term azithromycin therapy; Macrolide

Indexed keywords

AZITHROMYCIN; ANTIINFECTIVE AGENT;

AGED; ARTICLE; BACTERIAL COLONIZATION; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EMPHYSEMA; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXYGEN THERAPY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RETROSPECTIVE STUDY; TENESMUS; ACUTE DISEASE; ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; COMPLICATION; DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; PATIENT ATTITUDE; PROCEDURES; RESPIRATORY TRACT INFECTION; SMOKING; SPUTUM; STATISTICS AND NUMERICAL DATA;

ACUTE DISEASE; AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; SMOKING; SPUTUM;

EID: 85045286809     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2018.03.035     Document Type: Article

References (33)

1. Mathers, C.D., Loncar, D., Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3, 2006, e442.
2. Simoens, S., Laekeman, G., Decramer, M., Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir. Med. 107 (2013), 637–648.
3. Jemal, A., Ward, E., Hao, Y., Thun, M., Trends in the leading causes of death in the United States, 1970-2002. Jama 294 (2005), 1255–1259.
4. Bourbeau, J., Julien, M., Maltais, F., Rouleau, M., Beaupre, A., Begin, R., Renzi, P., Nault, D., Borycki, E., Schwartzman, K., Singh, R., Collet, J.P., Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Sante du Q. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch. Intern. Med. 163 (2003), 585–591.
5. Collet, J.P., Shapiro, P., Ernst, P., Renzi, T., Ducruet, T., Robinson, A., Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am. J. Respir. Crit. Care Med. 156 (1997), 1719–1724.
6. Connors, A.F. Jr., Dawson, N.V., Thomas, C., Harrell, F.E. Jr., Desbiens, N., Fulkerson, W.J., Kussin, P., Bellamy, P., Goldman, L., Knaus, W.A., Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 154 (1996), 959–967.
7. Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A., Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 (2002), 847–852.
8. Kanner, R.E., Anthonisen, N.R., Connett, J.E., Lung Health Study Research G. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med. 164 (2001), 358–364.
9. Miravitlles, M., Ferrer, M., Pont, A., Zalacain, R., Alvarez-Sala, J.L., Masa, F., Verea, H., Murio, C., Ros, F., Vidal, R., Group, I.S., Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59 (2004), 387–395.
10. Hurst, J.R., Vestbo, J., Anzueto, A., Locantore, N., Mullerova, H., Tal-Singer, R., Miller, B., Lomas, D.A., Agusti, A., Macnee, W., Calverley, P., Rennard, S., Wouters, E.F., Wedzicha, J.A., Evaluation of CLtIPSEI. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 363 (2010), 1128–1138.
11. James, G.D., Petersen, I., Nazareth, I., Wedzicha, J.A., Donaldson, G.C., Use of long-term antibiotic treatment in COPD patients in the UK: a retrospective cohort study. Prim. Care Respir. J. : J. Gen. Pract. Airways Group 22 (2013), 271–277.
12. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2017 Available from: http://goldcopd.org.
13. Wedzicha, J.A., Seemungal, T.A., COPD exacerbations: defining their cause and prevention. Lancet 370 (2007), 786–796.
14. Berkhof, F.F., Doornewaard-ten Hertog, N.E., Uil, S.M., Kerstjens, H.A., van den Berg, J.W., Azithromycin and cough-specific health status in patients with chronic obstructive pulmonary disease and chronic cough: a randomised controlled trial. Respir. Res., 14, 2013, 125.
15. Paggiaro, P.L., Chanez, P., Holz, O., Ind, P.W., Djukanovic, R., Maestrelli, P., Sterk, P.J., Sputum induction. Eur. Respir. J. Suppl. 37 (2002), 3s–8s.
16. Serisier, D.J., Martin, M.L., McGuckin, M.A., Lourie, R., Chen, A.C., Brain, B., Biga, S., Schlebusch, S., Dash, P., Bowler, S.D., Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial. Jama 309 (2013), 1260–1267.
17. Shafuddin, E., Mills, G.D., Holmes, M.D., Poole, P.J., Mullins, P.R., Black, P.N., A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease. J. Negat. Results Biomed., 14, 2015, 15.
18. Suresh Babu, K., Kastelik, J., Morjaria, J.B., Role of long term antibiotics in chronic respiratory diseases. Respir. Med. 107 (2013), 800–815.
19. Peckham, D.G., Macrolide antibiotics and cystic fibrosis. Thorax 57 (2002), 189–190.
20. Terada, K., Muro, S., Sato, S., Ohara, T., Haruna, A., Marumo, S., Kinose, D., Ogawa, E., Hoshino, Y., Niimi, A., Terada, T., Mishima, M., Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 63 (2008), 951–955.
21. Blondeau, K., Dupont, L.J., Mertens, V., Verleden, G., Malfroot, A., Vandenplas, Y., Hauser, B., Sifrim, D., Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis. Gut 57 (2008), 1049–1055.
22. Mertens, V., Blondeau, K., Pauwels, A., Farre, R., Vanaudenaerde, B., Vos, R., Verleden, G., Van Raemdonck, D.E., Dupont, L.J., Sifrim, D., Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig. Dis. Sci. 54 (2009), 972–979.
23. Equi, A., Balfour-Lynn, I.M., Bush, A., Rosenthal, M., Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002), 978–984.
24. Saiman, L., Marshall, B.C., Mayer-Hamblett, N., Burns, J.L., Quittner, A.L., Cibene, D.A., Coquillette, S., Fieberg, A.Y., Accurso, F.J., Campbell, P.W. 3rd, Macrolide Study, G., Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. Jama 290 (2003), 1749–1756.
25. Schultz, M.J., Macrolide activities beyond their antimicrobial effects: macrolides in diffuse panbronchiolitis and cystic fibrosis. J. Antimicrob. Chemother. 54 (2004), 21–28.
26. Wolter, J., Seeney, S., Bell, S., Bowler, S., Masel, P., McCormack, J., Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002), 212–216.
27. Albert, R.K., Connett, J., Bailey, W.C., Casaburi, R., Cooper, J.A. Jr., Criner, G.J., Curtis, J.L., Dransfield, M.T., Han, M.K., Lazarus, S.C., Make, B., Marchetti, N., Martinez, F.J., Madinger, N.E., McEvoy, C., Niewoehner, D.E., Porsasz, J., Price, C.S., Reilly, J., Scanlon, P.D., Sciurba, F.C., Scharf, S.M., Washko, G.R., Woodruff, P.G., Anthonisen, N.R., Network, C.C.R., Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 365 (2011), 689–698.
28. Seemungal, T.A., Wilkinson, T.M., Hurst, J.R., Perera, W.R., Sapsford, R.J., Wedzicha, J.A., Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 178 (2008), 1139–1147.
29. Ray, W.A., Murray, K.T., Hall, K., Arbogast, P.G., Stein, C.M., Azithromycin and the risk of cardiovascular death. N. Engl. J. Med. 366 (2012), 1881–1890.
30. Han, M.K., Tayob, N., Murray, S., Dransfield, M.T., Washko, G., Scanlon, P.D., Criner, G.J., Casaburi, R., Connett, J., Lazarus, S.C., Albert, R., Woodruff, P., Martinez, F.J., Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am. J. Respir. Crit. Care Med. 189 (2014), 1503–1508.
31. Yamaya, M., Azuma, A., Tanaka, H., Takizawa, H., Chida, K., Taguchi, Y., Mikasa, K., Kadota, J., Kudoh, S., Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: a retrospective multicenter analysis. J. Am. Geriatr. Soc. 56 (2008), 1358–1360.
32. Burr, L.D., Rogers, G.B., Chen, A.C., Hamilton, B.R., Pool, G.F., Taylor, S.L., Venter, D., Bowler, S.D., Biga, S., McGuckin, M.A., Macrolide treatment inhibits Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low-dose erythromycin study trial. Ann. Am. Thorac. Soc. 13 (2016), 1697–1703.
33. Rogers, G.B., Bruce, K.D., Martin, M.L., Burr, L.D., Serisier, D.J., The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir. Med. 2 (2014), 988–996.